Key Data For Amgen Medicines In Relapsed Multiple Myeloma And Acute Lymphoblastic Leukemia To Be ...

THOUSAND OAKS, Calif., Nov. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a number of important abstracts from the Company's oncology portfolio, including Kyprolis® (carfilzomib) for Injection, BLINCYTO® (blinatumomab), Nplate® (romiplostim) and Neulasta® (pegfilgrastim), are scheduled for presentation at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition, Dec. 5–8, 2015, in Orlando, Fla.   "We look forward to sharing new data that further demonstrate our commitment to studying innovative cancer therapies across the treatment continuum for patients with difficult-to-treat conditions," said Sean E. Harper, M.D.,...